HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.

Abstract
Radiation resistance in a subset of prostate tumors remains a challenge to prostate cancer radiotherapy. The current study on the effects of radiation on prostate cancer cells reveals that radiation programs an unpredicted resistance mechanism by upregulating acid ceramidase (AC). Irradiated cells demonstrated limited changes of ceramide levels while elevating levels of sphingosine and sphingosine-1-phosphate. By genetically downregulating AC with small interfering RNA (siRNA), we observed radiosensitization of cells using clonogenic and cytotoxicity assays. Conversely, AC overexpression further decreased sensitivity to radiation. We also observed that radiation-induced AC upregulation was sufficient to create cross-resistance to chemotherapy as demonstrated by decreased sensitivity to Taxol and C(6) ceramide compared to controls. Lower levels of caspase 3/7 activity were detected in cells pretreated with radiation, also indicating increased resistance. Finally, utilization of the small molecule AC inhibitor, LCL385, sensitized PPC-1 cells to radiation and significantly decreased tumor xenograft growth. These data suggest a new mechanism of cancer cell resistance to radiation, through upregulation of AC that is, in part, mediated by application of the therapy itself. An improved understanding of radiotherapy and the application of combination therapy achieved in this study offer new opportunities for the modulation of radiation effects in the treatment of cancer.
AuthorsAyman E M Mahdy, Joseph C Cheng, Jun Li, Saeed Elojeimy, William D Meacham, Lorianne S Turner, Aiping Bai, Christopher R Gault, Alex S McPherson, Nicole Garcia, Thomas H Beckham, Antonio Saad, Alicja Bielawska, Jacek Bielawski, Yusuf A Hannun, Thomas E Keane, Mohhammed I Taha, Hisham M Hammouda, James S Norris, Xiang Liu
JournalMolecular therapy : the journal of the American Society of Gene Therapy (Mol Ther) Vol. 17 Issue 3 Pg. 430-8 (Mar 2009) ISSN: 1525-0024 [Electronic] United States
PMID19107118 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • 2-N-(tetradecylamino)-1-phenyl-1,3-propanediol
  • Ceramides
  • Enzyme Inhibitors
  • Myristates
  • Propanolamines
  • RNA, Small Interfering
  • Radiation-Sensitizing Agents
  • Phosphotransferases (Alcohol Group Acceptor)
  • sphingosine kinase
  • Acid Ceramidase
  • Sphingosine
  • Paclitaxel
Topics
  • Acid Ceramidase (antagonists & inhibitors, genetics, metabolism)
  • Animals
  • Cell Line, Tumor
  • Ceramides (metabolism)
  • Enzyme Activation (drug effects)
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Myristates (pharmacology)
  • Paclitaxel (pharmacology)
  • Phosphotransferases (Alcohol Group Acceptor) (metabolism)
  • Propanolamines (pharmacology)
  • Prostatic Neoplasms (enzymology, genetics)
  • RNA, Small Interfering (genetics)
  • Radiation-Sensitizing Agents (pharmacology)
  • Sensitivity and Specificity
  • Sphingosine (analogs & derivatives, metabolism)
  • Up-Regulation (drug effects, radiation effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: